A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

NCT03026803 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
4
Enrollment
OTHER
Sponsor class

Stopped Due to Sorafenib became first line treatment for HCC, the designed treatment became less competitive. The company Sanofi decided not to continue to support

Conditions

Interventions

Sponsor

City of Hope Medical Center

Collaborators